Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study
Clinical trial NCT03639311 · COMPLETED
Trial details
- NCT number
- NCT03639311
- Sponsor
- ViiV Healthcare
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-24
- Primary completion
- 2019-12-11
- Enrollment
- 97
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.